230 related articles for article (PubMed ID: 36870047)
1. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
[TBL] [Abstract][Full Text] [Related]
5. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
[No Abstract] [Full Text] [Related]
6. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
Bhatt AS; Vaduganathan M; Claggett BL; Kulac IJ; Anand IS; Desai AS; Fang JC; Hernandez AF; Jhund PS; Kosiborod MN; Sabatine MS; Shah SJ; Vardeny O; McMurray JJV; Solomon SD; Gaziano TA
J Am Heart Assoc; 2024 Mar; 13(5):e032279. PubMed ID: 38390793
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
Yan BW; Spahillari A; Pandya A
Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Zhou J; Liew D; Kaye DM; Zoungas S; Stub D
Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008638. PubMed ID: 36252135
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
Hallinen T; Kivelä S; Soini E; Harjola VP; Pesonen M
Clinicoecon Outcomes Res; 2023; 15():1-13. PubMed ID: 36636485
[TBL] [Abstract][Full Text] [Related]
12. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
[TBL] [Abstract][Full Text] [Related]
13. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Starr JA; Pinner NA
Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
Tang Y; Sang H
Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
[No Abstract] [Full Text] [Related]
15. SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study.
Lu H; Shang P; Zhou D
Front Pharmacol; 2023; 14():1155210. PubMed ID: 37771722
[No Abstract] [Full Text] [Related]
16. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
[TBL] [Abstract][Full Text] [Related]
19. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
